RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

This study tested an investigational RSV vaccine in adults aged 18-49 who have chronic health conditions that put them at higher risk for severe RSV illness. Researchers compared the vaccine's safety and the immune response it triggered in these younger adults to the response in …

This study tested a single-dose RSV vaccine in adults aged 60 and older. It aimed to see if the vaccine triggered a strong immune response in participants from China that was similar to the response seen in older adults from other countries in a previous successful trial. Researc…

This study tested a new vaccine designed to protect older adults from severe Respiratory Syncytial Virus (RSV) lung infections. It involved 751 Indian participants aged 50 and older, including those with underlying health conditions like heart or lung disease. Researchers gave a …

This study tested whether a new antibody injection called TNM001 could prevent serious lung infections caused by Respiratory Syncytial Virus (RSV) in high-risk infants. About 315 infants under 1 year old entering their first RSV season received either the antibody or a placebo sh…

This study tested whether an injection called TNM001 could safely prevent serious lower respiratory tract infections caused by RSV in infants under one year old. Over 2,200 babies, including some born prematurely or with certain heart or lung conditions, received either the injec…

This study tested whether a new RSV vaccine and a COVID-19 booster shot could be given safely at the same time to adults aged 50 and older. Researchers compared the immune response and side effects when the shots were given together versus separately. The goal was to see if getti…

This study followed people who had received an RSV vaccine or a placebo in earlier trials to see if the vaccine affected their health or their baby's health in pregnancies that happened later. It did not give any new treatments; it only collected safety information from over 3,80…